Table 2. Clinical Data for TEL/AML... | American Society of Hematology

Table 2.

Clinical Data for TEL/AML 1-Positive Patients

Patient No.	Sex	Initial Leukemia							First Relapse						Second Relapse
		Age (yr)	Immunophenotype	WBC	Diagnosis Date	TEL/AML1	Therapy	CR	Relapse Date	WBC	TEL/AML1	Site	Therapy	Second CR (yr)	Relapse Date	Site	TEL/AML1
				(×10⁹/L)				(yr)		(×10⁹/L)
87086	M	13.9	c-ALL	46.0	2/18/87	PCR⁺	BFM 86-RG	3.9	1/4/91	12.0	No mat	BM	ALL-REZ 90	5.5	7/1/96	BM	PCR⁺
88615	F	3.5	c-ALL	15.6	12/14/88	FISH⁺	BFM 86-RG	3.6	7/31/92	12.4	PCR⁺	BM	ALL-REZ 90	3.9	6/25/96	BM	PCR⁺
89100	M	3.0	c-ALL	84.9	3/6/89	No mat	BFM 86-RG	4.1	3/24/93	3.1	No mat	BM	ALL-REZ 90	3.5	9/9/96	BM	PCR⁺, FISH⁺
90568	M	5.6	Pre-B-ALL	6.1	12/20/90	No mat	BFM 90-SR	2.5	6/28/93	3.1	PCR+	BM	ALL-REZ 90	3.2	8/28/96	BM/T	PCR⁺, FISH⁺
93473	M	6.3	c-ALL	18.9	9/23/93	PCR⁺	BFM 90-MR	2.9	8/21/96	8.6	PCR⁺, FISH⁺	BM	ALL-REZ P95
94112	F	3.4	c-ALL	6.7	2/14/94	PCR⁺	CoALL-05-92-LR	2.7	10/14/96	3.9	PCR⁺, FISH⁺	BM	ALL-REZ P95
94565	F	3.3	c-ALL	5.6	10/5/94	PCR⁺	CoALL-05-92-HR	2.1	11/1/96	5.0	PCR⁺, FISH⁺	BM	ALL-REZ P95
96526	F	5.9	c-ALL^*	ND	1/22/93	No mat	AML therapy	3.6	9/14/96	9.5	PCR⁺, FISH⁺	BM/CNS
96569	M	4.1	c-ALL	9.2	9/3/93	No mat	BFM 90-SR	3.1	10/7/96	4.3	PCR⁺, FISH⁺	BM/CNS	ALL-REZ P95

Patient No.	Sex	Initial Leukemia							First Relapse						Second Relapse
		Age (yr)	Immunophenotype	WBC	Diagnosis Date	TEL/AML1	Therapy	CR	Relapse Date	WBC	TEL/AML1	Site	Therapy	Second CR (yr)	Relapse Date	Site	TEL/AML1
				(×10⁹/L)				(yr)		(×10⁹/L)
87086	M	13.9	c-ALL	46.0	2/18/87	PCR⁺	BFM 86-RG	3.9	1/4/91	12.0	No mat	BM	ALL-REZ 90	5.5	7/1/96	BM	PCR⁺
88615	F	3.5	c-ALL	15.6	12/14/88	FISH⁺	BFM 86-RG	3.6	7/31/92	12.4	PCR⁺	BM	ALL-REZ 90	3.9	6/25/96	BM	PCR⁺
89100	M	3.0	c-ALL	84.9	3/6/89	No mat	BFM 86-RG	4.1	3/24/93	3.1	No mat	BM	ALL-REZ 90	3.5	9/9/96	BM	PCR⁺, FISH⁺
90568	M	5.6	Pre-B-ALL	6.1	12/20/90	No mat	BFM 90-SR	2.5	6/28/93	3.1	PCR+	BM	ALL-REZ 90	3.2	8/28/96	BM/T	PCR⁺, FISH⁺
93473	M	6.3	c-ALL	18.9	9/23/93	PCR⁺	BFM 90-MR	2.9	8/21/96	8.6	PCR⁺, FISH⁺	BM	ALL-REZ P95
94112	F	3.4	c-ALL	6.7	2/14/94	PCR⁺	CoALL-05-92-LR	2.7	10/14/96	3.9	PCR⁺, FISH⁺	BM	ALL-REZ P95
94565	F	3.3	c-ALL	5.6	10/5/94	PCR⁺	CoALL-05-92-HR	2.1	11/1/96	5.0	PCR⁺, FISH⁺	BM	ALL-REZ P95
96526	F	5.9	c-ALL^*	ND	1/22/93	No mat	AML therapy	3.6	9/14/96	9.5	PCR⁺, FISH⁺	BM/CNS
96569	M	4.1	c-ALL	9.2	9/3/93	No mat	BFM 90-SR	3.1	10/7/96	4.3	PCR⁺, FISH⁺	BM/CNS	ALL-REZ P95

Abbreviations: ND, not determined; no mat, no material available; BM, bone marrow; T, testis; RG, risk group; SR, standard risk; MR, medium risk; LR, low risk; HR, high risk; ALL-REZ, ALL relapse therapy trials; BFM, Berlin-Frankfurt-Münster therapy trials; CoALL, Cooperative ALL therapy trials.

Immunophenotype of relapse; this patient was diagnosed and treated in Turkey as AML.

View Large

This Feature Is Available To Subscribers Only